Archives
-
Ofev Drug Fails in Mesothelioma Clinical Trial
Ofev (nintedanib), a once-promising drug for mesothelioma, has failed to slow disease progression in a clinical trial. The immunotherapy drug was part of a multicenter study across 27 countries. Ofev had shown considerable potential in previous studies.
Latest Research Articles
-
'Mega-fires' may be too extreme even for a bird that loves fire
-
Can the Gambling Industry Do More to Combat Climate Change?
-
Species Aren't Adapting Fast Enough to Cope With Climate Change, According to New Study
-
Super-Resolution Microscopy Sheds Light on How Dementia Protein Becomes Dysfunctional
-
To Learn How Poison Frogs are Adapting to Warmer Temperatures, Scientists Got Crafty
-
Endometrial Diseases Can Be Imitated in a Lab Dish, New Study Shows
-
Knockout Mice are Guide to New Genes for Eye and Skin Disorders
-
From Japanese Basket Weaving Art to Nanotechnology with Ion Beams
-
UNH Research Finds Shale Natural Gas Development Impacting Recreationists
-
Travelers Use Rail for Multi-Destination Trips to Reduce Carbon Footprint
-
Barn Owls May Hold Key to Navigation and Location
-
WPI Liquid Biopsy Chip Snares Circulating Tumor Cells in Blood Drops from Cancer Patients
most popular
-
Beyond the Aurora: How Do Solar Flares Affect Electronics
-
Mauna Loa’s Lava Study Confirms Geologists’ Early Warning of Eruption
-
WhaleX Team Creates Synthetic Whale Poop to Revive Ocean Ecosystems
-
How AI and IoT are Transforming Sustainability in Real Estate
-
Donut Inside Earth Could Hold Clues to Planet's Seizmic Activity
